{"instruction": "You are an expert in event extraction. Please extract events from the input that conform to the schema definition. Return an empty list for events that do not exist, and return NAN for arguments that do not exist. If an argument has multiple values, please return a list. Respond in the format of a JSON string.", "schema": [{"event_type": "potential therapeutic event", "trigger": true, "arguments": ["Treatment.Freq", "Treatment.Drug", "Subject.Race", "Subject", "Subject.Gender", "Treatment.Duration", "Subject.Age", "Treatment.Dosage", "Subject.Population", "Effect", "Treatment", "Treatment.Route", "Treatment.Time_elapsed", "Combination.Drug", "Treatment.Disorder", "Subject.Disorder"]}, {"event_type": "adverse event", "trigger": true, "arguments": ["Subject.Gender", "Subject.Age", "Treatment.Time_elapsed", "Treatment.Freq", "Combination.Drug", "Subject.Population", "Treatment", "Subject", "Subject.Disorder", "Treatment.Disorder", "Treatment.Route"]}], "input": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302."}
{"potential therapeutic event": [{"trigger": "prolongs survival ", "arguments": {"Treatment.Freq": "NAN", "Treatment.Drug": "Abiraterone acetate", "Subject.Race": "NAN", "Subject": "men with metastatic castration-resistant prostate cancer (mCRPC)", "Subject.Gender": "men", "Treatment.Duration": "NAN", "Subject.Age": "NAN", "Treatment.Dosage": "NAN", "Subject.Population": "NAN", "Effect": "NAN", "Treatment": "Abiraterone acetate, an androgen biosynthesis inhibitor", "Treatment.Route": "NAN", "Treatment.Time_elapsed": "NAN", "Combination.Drug": "NAN", "Treatment.Disorder": "metastatic castration-resistant prostate cancer", "Subject.Disorder": "NAN"}}], "adverse event": []}